Global Viral Vector Manufacturing Market Size & Trends Report Segmented by Vector Type (Viral Vectors, Plasmid DNA), Indication (Cancer, Genetic Disorders, Infectious Diseases), Application, Workflow, End-user Analysis & Regional Forecast to 2030
The global viral vector manufacturing market is expected to grow at a CAGR of ~20% during the forecast period. The rising prevalence of genetic disorders and cancer, surge in the number of gene therapy clinical trials, pandemic-driven vaccine development and rising outsourcing to CDMOs for scalable manufacturing are some of the key factors driving the market growth. However, high manufacturing costs of viral vector products remain a major constraint for the viral vector manufacturing market. To learn more about the research report, download a sample report.
Overview
Viral vector manufacturing is a specialized biotechnological process in which viruses are modified for delivering genetic material into cells. These vectors are essential for gene therapy, vaccine development, and cell-based therapies. Unlike conventional methods, viral vectors require highly controlled environments to ensure their safety and efficacy. Some of the key viral vectors include adenoviruses, adeno-associated viruses (AAVs), lentiviruses, and retroviruses, each with distinct advantages based on stability, tissue targeting, and gene size capacity. Emerging trends in manufacturing include automation, closed systems, and continuous processing to improve yield and reduce costs. Overall, viral vector manufacturing is central to advancing next-generation therapeutics and personalized medicine.
To learn more about this report, download the PDF brochure
Viral vector manufacturing gains momentum with advances in genetic disorder and cancer treatments
The increasing prevalence of genetic disorders and cancers is a major force driving the demand for the viral vector manufacturing market. Conditions like hemophilia and spinal muscular atrophy, which were once considered untreatable, are now being treated through advanced gene therapies that rely on viral vectors to deliver corrective genes. According to an article published by the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with nearly 10 million deaths annually, but recent advances in gene-modified therapies have marked a significant breakthrough in its treatment. Further, the emergence of gene-modified therapies such as CAR-T cell therapies and oncolytic virotherapies has revolutionized cancer treatment. These therapies mostly rely on viral vectors for genetic modification of immune cells or direct tumor targeting. The expansion of oncology-focused gene therapies is prompting investments in advanced bioprocessing technologies and CDMO partnerships. Lastly, improved diagnostics and patient awareness have expanded the treatment pool, further fueling the market.
To learn more about this report, download the PDF brochure
AI and automation accelerate viral vector manufacturing timelines
The integration of automation and AI into viral vector manufacturing is revolutionizing how therapies are developed and delivered. Smart bioprocessing tools enable real-time monitoring, predictive analytics, and adaptive control of production parameters, ensuring consistent vector quality and minimizing human error. Automation streamlines repetitive tasks, such as cell culture maintenance or purification, while AI algorithms optimize yield by analyzing vast amounts of process data. These advances significantly reduce operational costs, improve batch-to-batch consistency, and shorten production cycles, making therapies more accessible to patients worldwide.
Recent developments in the viral vector manufacturing market
Viral vector manufacturing is advancing rapidly, with companies expanding capabilities and introducing innovations to meet the growing demand for gene and cell therapies. Recent milestones from facility expansions to record production achievements, among others, show how the market is scaling up to make these therapies more accessible to patients worldwide. For instance,
- In June 2025, US-based CDMO ProBio opened its flagship 128,000 sq ft GMP facility in Hopewell, New Jersey, to expand plasmid DNA and viral vector manufacturing capacity, supporting clinical development and large-scale production of gene and cell therapies
- In July 2024, Belgian CDMO Kaneka Eurogentec set a new benchmark by producing 1 kg of plasmid DNA in a single GMP batch, for a major drug developer, enabling high-volume gene therapy production
- In March 2024, Polyplus released pPLUS® AAV-RC2, a RepCap plasmid specifically designed for AAV2 vector production, expanding raw material options for AAV-based gene therapies
Competitive Landscape Analysis
The global viral vector manufacturing market is marked by the presence of established and emerging market players, including Lonza Group; Catalent Inc.; Fujifilm Diosynth Biotechnologies; Merck KGaA; Thermo Fisher Scientific Inc.; Astellas Pharma Inc; Sanofi S.A.; Charles River Laboratories; Miltenyi Biotec GmbH; Sartorius AG; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Report Scope
| Report Metric | Details |
| Base Year Considered | 2024 |
| Historical Data | 2023 - 2024 |
| Forecast Period | 2025 – 2030 |
| Growth Rate | ~20% |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Vector Type, Indication, Application, Workflow, and End-user |
| Regional Scope |
|
| Key Companies Mapped | Lonza Group; Catalent Inc.; Fujifilm Diosynth Biotechnologies; Merck KGaA; Thermo Fisher Scientific Inc.; Astellas Pharma Inc; Sanofi S.A.; Charles River Laboratories; Miltenyi Biotec GmbH; and Sartorius AG; among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Â
Global Viral Vector Manufacturing Market Segmentation
This report by Medi-Tech Insights provides the size of the global viral vector manufacturing market at the regional- and country-level from 2023 to 2030. The report further segments the market based on vector type, indication, application, workflow, and end-user.
Market Size & Forecast (2023-2030), By Vector Type, USD Million
- Viral Vectors
- Adenoviruses
- AAVs
- Lentiviruses
- Retroviruses
- Others
- Plasmid DNA
Market Size & Forecast (2023-2030), By Indication, USD Million
- Cancer
- Genetic Disorders
- Infectious Diseases
- Neurological Disorders
- Others
Market Size & Forecast (2023-2030), By Application, USD Million
- Gene & Cell Therapy
- Vaccinology
- Research
Market Size & Forecast (2023-2030), By Workflow, USD Million
- Upstream Processing
- Downstream Processing
- Quality Control & Analytics
Market Size & Forecast (2023-2030), By End-user, USD Million
- Biopharma Companies
- Academic & Research Institutes
- CDMOs
- Others
Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the viral vector manufacturing market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the viral vector manufacturing market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Stakeholders from Hospitals, Biotechnological Companies, and Others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
Features of the Report
- Comprehensive Market Coverage
- Market Size and Forecast
- Geographic & Segment Deep Dives
- Strategic Insights & Competitive Landscape
- Timely & Updated Data
- Growth Indicators & Future Outlook
- Quick Turnaround on Queries
- Analyst Support
- Report Customization Available
- Reports in PDF & Excel
